Hyperphosphatemia is a common complication in patients with chronic kidney disease
(CKD), particularly in those requiring renal replacement therapy. The importance of …

A series of problems including osteopathy, abnormal serum data, and vascular calcification
associated with chronic kidney disease (CKD) are now collectively called CKD-mineral bone …

As in 2011, when the Spanish Society of Nephrology (SEN) published the Spanish
adaptation to the Kidney Disease: Improving Global Outcomes (KDIGO) universal Guideline …

Chronic kidney disease (CKD) is frequently accompanied by hyperphosphatemia. High
serum phosphate usually requires dietary measures, adequate dialysis prescription and/or …

Al igual a como ocurrió en el año 2011, cuando la Sociedad Española de Nefrología (SEN)
publicó la adaptación española a las guías universales Kidney Disease Initiative Global …

In this review, significant applications of lanthanides and their compounds in bone tissue
engineering are described, with an emphasis on coordination compounds based on wide …

Background Besides reducing hyperphosphatemia in chronic kidney disease (CKD)
patients, phosphate lowering agents might provide beneficial effects on clinical and …

Patients with progressive chronic kidney disease (CKD) commonly develop mineral and
bone abnormalities and extraskeletal calcifications with following increased cardiovascular …

Introduction Coronary artery calcification and cardiac abnormalities are common in
hemodialysis patients. The value of lanthanum carbonate over calcium‐based phosphate …

Background: Serum intact fibroblast growth factor 23 (FGF23) levels are progressively
increased in relation to the severity of kidney dysfunction. High serum intact FGF23 …